Bliss GVS Pharma
NSE: BLISSGVS · Pharmaceuticals
Snapshot
Unlock Bliss GVS Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Bliss GVS Pharma Limited is an Indian pharmaceutical company engaged in the development, manufacturing, and marketing of a diverse range of formulations. Its extensive product portfolio spans various therapeutic categories, including anti-infectives, analgesics, and nutritional supplements, alongside various over-the-counter healthcare products.
Business Model
The company generates revenue by manufacturing and selling a wide array of pharmaceutical formulations and healthcare products across domestic and international markets. It leverages a broad manufacturing capability to produce diverse dosage forms, including tablets, injections, and topical preparations.
- Incorporation Year:1984
Growth Outlook
Growth is driven by the company's extensive product pipeline and its focus on expanding its footprint in both domestic and export markets. The breadth of its therapeutic offerings allows it to address diverse healthcare needs across multiple segments.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality standards and manufacturing audits by domestic and international health authorities.
- Export Market Volatility. As an exporter, the company is susceptible to geopolitical instability, currency fluctuations, and varying regulatory requirements in international markets.
- Intense Competition. The pharmaceutical sector is highly competitive, potentially impacting pricing power and market share for generic and over-the-counter products.
- Raw Material Price Fluctuations. Volatility in the cost of active pharmaceutical ingredients and other raw materials can significantly impact profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Bliss GVS Pharma and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,074 Cr
TTM · consolidated
NET PROFIT
₹166 Cr
TTM · consolidated
EPS
₹15.22
TTM · consolidated
RETURN ON EQUITY
13.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
19.1%
TTM · consolidated
P/E
40.6×
Q2 FY27 · consolidated
EV/EBITDA
24.1x
Q2 FY27 · consolidated
EBITDA MARGIN
26.4%
TTM · consolidated
NET PROFIT MARGIN
17.0%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Bliss GVS PharmaBLISSGVS | ₹6,881 Cr | 40.6× | 24.12 | 24.9% | 26.4% | 13.7% | 19.1% | +293.5% |
Sanofi India LimitedSANOFI | ₹7,379 Cr | 21.2× | 13.28 | -5.7% | 29.0% | 45.3% | 59.5% | -29.9% |
Supriya Lifescience LimitedSUPRIYA | ₹6,819 Cr | 34.0× | 22.51 | 28.1% | 34.5% | 18.1% | 23.8% | +7.9% |
Morepen Laboratories LimitedMOREPENLAB | ₹6,211 Cr | 31.4× | 21.02 | 30.2% | 13.2% | 14.6% | 18.8% | +126.3% |
FDC LimitedFDC | ₹6,138 Cr | 19.8× | 12.15 | 10.2% | 21.9% | 12.3% | 16.1% | -17.3% |
Innova Captab LimitedINNOVACAP | ₹5,867 Cr | 37.2× | 23.09 | 34.5% | 15.4% | 15.0% | 17.4% | +20.5% |
As of Q2 FY27
Financials
Bliss GVS Pharma
NSE: BLISSGVS · Pharmaceuticals
Snapshot
Unlock Bliss GVS Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Bliss GVS Pharma Limited is an Indian pharmaceutical company engaged in the development, manufacturing, and marketing of a diverse range of formulations. Its extensive product portfolio spans various therapeutic categories, including anti-infectives, analgesics, and nutritional supplements, alongside various over-the-counter healthcare products.
Business Model
The company generates revenue by manufacturing and selling a wide array of pharmaceutical formulations and healthcare products across domestic and international markets. It leverages a broad manufacturing capability to produce diverse dosage forms, including tablets, injections, and topical preparations.
- Incorporation Year:1984
Growth Outlook
Growth is driven by the company's extensive product pipeline and its focus on expanding its footprint in both domestic and export markets. The breadth of its therapeutic offerings allows it to address diverse healthcare needs across multiple segments.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality standards and manufacturing audits by domestic and international health authorities.
- Export Market Volatility. As an exporter, the company is susceptible to geopolitical instability, currency fluctuations, and varying regulatory requirements in international markets.
- Intense Competition. The pharmaceutical sector is highly competitive, potentially impacting pricing power and market share for generic and over-the-counter products.
- Raw Material Price Fluctuations. Volatility in the cost of active pharmaceutical ingredients and other raw materials can significantly impact profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Bliss GVS Pharma and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,074 Cr
TTM · consolidated
NET PROFIT
₹166 Cr
TTM · consolidated
EPS
₹15.22
TTM · consolidated
RETURN ON EQUITY
13.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
19.1%
TTM · consolidated
P/E
40.6x
Q2 FY27 · consolidated
EV/EBITDA
24.1x
Q2 FY27 · consolidated
EBITDA MARGIN
26.4%
TTM · consolidated
NET PROFIT MARGIN
17.0%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
As of Q2 FY27